- Home
- ICON vs EVOK Comparison
ICON vs EVOK Comparison
Compare ICON & EVOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICON
- EVOK
- Stock Information
- Founded
- ICON 2023
- EVOK 2007
- Country
- ICON Greece
- EVOK United States
- Employees
- ICON N/A
- EVOK N/A
- Industry
- ICON
- EVOK Biotechnology: Pharmaceutical Preparations
- Sector
- ICON
- EVOK Health Care
- Exchange
- ICON Nasdaq
- EVOK Nasdaq
- Market Cap
- ICON 3.6M
- EVOK 4.2M
- IPO Year
- ICON 2024
- EVOK 2013
- Fundamental
- Price
- ICON $1.79
- EVOK $3.22
- Analyst Decision
- ICON Strong Buy
- EVOK
- Analyst Count
- ICON 1
- EVOK 0
- Target Price
- ICON $4.50
- EVOK N/A
- AVG Volume (30 Days)
- ICON 116.0K
- EVOK 13.8K
- Earning Date
- ICON 05-23-2025
- EVOK 05-13-2025
- Dividend Yield
- ICON 195.06%
- EVOK N/A
- EPS Growth
- ICON N/A
- EVOK N/A
- EPS
- ICON N/A
- EVOK N/A
- Revenue
- ICON $5,309,000.00
- EVOK $11,594,083.00
- Revenue This Year
- ICON $76.76
- EVOK $58.84
- Revenue Next Year
- ICON $30.43
- EVOK $58.11
- P/E Ratio
- ICON N/A
- EVOK N/A
- Revenue Growth
- ICON 18.61
- EVOK 89.89
- 52 Week Low
- ICON $1.60
- EVOK $1.94
- 52 Week High
- ICON $154.00
- EVOK $12.32
- Technical
- Relative Strength Index (RSI)
- ICON N/A
- EVOK 62.15
- Support Level
- ICON N/A
- EVOK $3.00
- Resistance Level
- ICON N/A
- EVOK $3.29
- Average True Range (ATR)
- ICON 0.00
- EVOK 0.21
- MACD
- ICON 0.00
- EVOK 0.05
- Stochastic Oscillator
- ICON 0.00
- EVOK 80.82
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a Growth-oriented company that operates as a holding company for the purpose of acquiring, owning, chartering and operating dry bulk vessels through its subsidiaries. The company generates its revenues by chartering the Initial Vessels to regional and international dry bulk operators, commodity traders and end users.
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.